Drugs / Inolimomab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT04289103 | Oct 2021 → Dec 2022 | chronic graft versus host disease | ElsaLys Biotech | Unknown | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05047328 | — | acute graft versus host disease | ElsaLys Biotech | Available | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02694770 Comparator | Jul 2016 → Sep 2017 | acute graft versus host disease | AbGenomics B.V Taiwan Branch | Withdrawn | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Inolimomab | “methotrexate, basiliximab, daclizumab, inolimomab, denileukin diftitox, alemtuzumab, ATG+ etanercept” NCT02694770 ↗ |
| Known as | BT-563 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108370 ↗ |
| Known as | Leukotac | “Inolimomab (Leukotac)” NCT04289103 ↗ |
| Action | Inhibit | “Interleukin-2 receptor alpha chain antagonist” CHEMBL2108370 ↗ |
| Modality | Monoclonal antibody | “Inolimomab is an IgG1 mouse monoclonal antibody” NCT05047328 ↗ |
| Target | IL2RA | “Interleukin-2 receptor alpha chain antagonist” CHEMBL2108370 ↗ |